FibroBiologics (FBLG) announced that The Nasdaq Stock Market has confirmed that the company has demonstrated compliance with all applicable criteria for continued listing on The Nasdaq Capital Market, including the $2.5M stockholders’ equity requirement and the $1.00 bid price requirement. The company has now successfully resolved its Nasdaq compliance issues but will remain subject to one-year monitoring periods for both stockholders’ equity and bid price compliance.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FBLG:
- FibroBiologics Lowers Quorum Requirement in Amended Bylaws
- FibroBiologics target adjusted to $8 at H.C. Wainwright after reverse split
- FibroBiologics Ends Texas Sublease, Consolidates Houston Operations
- FBLG Earnings this Week: How Will it Perform?
- FibroBiologics Implements One-for-Twenty Reverse Stock Split